Evidence map›Paper›PMID 40483284›Full record

ArticleDrug delivery and translational research2025

Development of an in-situ forming implant system for levodopa and carbidopa for the treatment of parkinson's disease.

Deepa D Nakmode, Sadikalmahdi Abdella, Yunmei Song, Sanjay Garg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Deepa D NakmodeCentre for Pharmaceutical Innovation, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.
Sadikalmahdi AbdellaCentre for Pharmaceutical Innovation, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.
Yunmei SongCentre for Pharmaceutical Innovation, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia.
Sanjay GargCentre for Pharmaceutical Innovation, University of South Australia, North Terrace, Adelaide, SA, 5000, Australia. Sanjay.Garg@unisa.edu.au.ORCID 0000-0001-7253-2629

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-acting injectables have gained attraction as a system for treating chronic conditions due to their increased efficacy, safety, and patient compliance. Currently, patients with Parkinsons need to administer oral medications multiple times a day which imposes the significant risk of non-compliance. This study aimed to design an in-situ implant-forming system for controlled delivery of levodopa and carbidopa for up to 1 week which will reduce the need for multiple dosing. The combination of poly-lactic-co-glycolic acid (PLGA

Indexed as

Antiparkinson AgentsCarbidopaLevodopaParkinson DiseaseAnimalsDelayed-Action PreparationsDrug Delivery SystemsDrug ImplantsDrug LiberationLactic AcidPolylactic Acid-Polyglycolic Acid CopolymerPolymethacrylic AcidsViscosityAntiparkinson AgentsCarbidopaDelayed-Action PreparationsDrug ImplantsLactic AcidLevodopaPolylactic Acid-Polyglycolic Acid CopolymerPolymethacrylic Acids

Identifiers

PMID40483284
PMCPMC12507947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.